15 August 2013
Instem plc
("Instem", or the "Company")
Notice of Interim Results
Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, will be announcing its unaudited interim results for the six months ended 30 June 2013, on Wednesday 25 September 2013.
Management will be hosting a presentation for analysts on the day of results at 11am at the offices of N+1 Singer: One Bartholomew Lane, London, EC2N 2AX.
Analysts who wish to attend the presentation should register their interest with Jasper Randall, contactable at j.randall@newgatethreadneedle.com or 020 7653 9845.
For further information, please contact:
Instem plc |
+44 (0) 1785 825 600 |
Phil Reason, CEO |
|
Nigel Goldsmith, CFO
|
|
|
|
N+1 Singer (Nominated Adviser & Broker) |
+44 (0) 20 7496 3000 |
Richard Lindley |
|
Aubrey Powell |
|
|
|
Newgate Threadneedle |
+44 (0) 20 7653 9850 |
|
|
Fiona Conroy Caroline Evans-Jones Jasper Randall |
|
About Instem plc
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.
To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/